Cytoreductive Surgery

Cytoreductive surgery (often called "debulking") is an operation that removes as much visible tumor as possible from inside the abdomen or chest. The goal is not always to cure but to reduce the total amount of cancer so that other treatments, most often heated chemotherapy washed directly into the body cavity, can work more effectively. In asbestos-related cancers, it is most commonly used for peritoneal mesothelioma.

Origin

The term combines the Greek kytos (cell) with the Latin reducere (to bring back or diminish). The modern surgical approach was developed in the 1980s and 1990s by Dr. Paul Sugarbaker and others for advanced abdominal cancers, and was later adapted for peritoneal mesothelioma when combined with HIPEC (heated intraperitoneal chemotherapy).

Significance in Asbestos Context

For patients with peritoneal mesothelioma, cytoreductive surgery combined with HIPEC is currently the treatment most associated with long-term survival. Some patients live a decade or longer after the procedure. Eligibility depends on how widely the tumor has spread, the cell type (epithelioid does best), the patient's overall health, and whether a specialized surgical team is available. Because the operation is long, complex, and only performed at select centers, getting evaluated at a high-volume mesothelioma program early in the diagnosis can change the entire treatment trajectory. In legal claims, undergoing this surgery (and the recovery, time off work, and future medical needs that follow) is part of documenting the disease's impact on the patient's life.

Example Sentence

After her peritoneal mesothelioma diagnosis, she traveled to a specialty center for cytoreductive surgery with HIPEC, which her oncologist explained offered the best chance at extended survival.

Related Terms

HIPEC, Peritoneal Mesothelioma, Pleurectomy/Decortication, Extrapleural Pneumonectomy, Epithelioid Mesothelioma, Peritoneal Cancer Index

Notes

• Ask whether you are a candidate for cytoreductive surgery with HIPEC before starting systemic chemotherapy, because pre-surgical chemotherapy choices can affect surgical eligibility at some centers.
• Seek evaluation at a high-volume mesothelioma center (such as MD Anderson, Memorial Sloan Kettering, Brigham and Women's, Moffitt, or Washington Cancer Institute). Outcomes are strongly tied to surgical team experience.
• Request a copy of the operative report, pathology report, and the surgeon's documented Peritoneal Cancer Index (PCI) score and completeness-of-cytoreduction (CC) score; these documents are important for both future medical care and any legal claim.
• Keep records of all travel, lodging, lost wages, and caregiver costs related to the surgery. These expenses are often recoverable as damages.